Related Experiment Video
Updated: Aug 24, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer]
Tian-kui Qiao1, Dao-an Zhou, Li Xin
1Department of Radiotherapy, Jinshan Hospital, Fudan University, Shanghai 200540, China.
Objective:
To observe the effect of concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer.
Methods:
Ninety patients with limited stage small cell lung cancer were randomized into two groups, concurrent treatment group (group A) and sequential treatment group (group B). All the patients in two groups received radiotherapy (60 Gy in 6 weeks) and six courses of chemotherapy (carboplatin and etoposide). Radiotherapy was started in the first course of chemotherapy in group A. Patients of group B were treated by radiation between the fourth and the fifth course of chemotherapy.
Results:
The median survival time was 26 months in group A and 19 months in group B. The 5-year survival rate was 27% in group A and 16% in group B. The major toxic reactions were grade III-IV myelosuppression. The differences of two groups were significant (P < 0.05).
Conclusion:
Concurrent radiotherapy combined with carboplatin and etoposide can significantly improve median survival time and 5-year survival rate of patients with limited stage small cell lung cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...